PT  - JOURNAL ARTICLE
AU  - Misra-Press, Anita
ED  - Braun, Ada
TI  - Novel Compound Beneficial as Adjunct to Antibody-Based Therapy for Stage IV NSCLC Patients
DP  - 2015 Jun 19
TA  - MD Conference Express
PG  - 14--15
VI  - 15
IP  - 8
4099  - http://mdc.sagepub.com/content/15/8/14.2.short
4100  - http://mdc.sagepub.com/content/15/8/14.2.full
AB  - This randomized, phase 2 trial evaluated PGG beta-glucan, a novel immune modulator, in combination with bevacizumab and carboplatin/paclitaxel as first-line treatment for patients with stage IV non–small cell lung cancer. Though not statistically significant, the results for the primary and secondary end points favor the PGG beta-glucan–treated group and warrant further study of PGG beta-glucan as an adjunct to bevacizumab-containing chemotherapy regimens.